NO20060189L - Antistoffer mot interleukin-22 og anvendelse derav - Google Patents

Antistoffer mot interleukin-22 og anvendelse derav

Info

Publication number: NO20060189L
Authority: NO; Norway
Prior art keywords: antibodies; interleukin; disclosed; associated immune; disorders
Prior art date: 2003-06-23

Application number

NO20060189A

Other languages

English (en)

Norwegian (no)

Inventor

Kathleen Tomkinson

Jing Li

Xiang-Yang Tan

Debra D Pittman

Geertruida M Veldan

Lynette Fouser

Original Assignee

Genetics Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-06-23

Filing date

2006-01-12

Publication date

2006-03-20

2006-01-12 Application filed by Genetics Inst filed Critical Genetics Inst

2006-03-20 Publication of NO20060189L publication Critical patent/NO20060189L/no

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/08—Antibacterial agents for leprosy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Immunology (AREA)
Diabetes (AREA)
Hematology (AREA)
Neurology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Biophysics (AREA)
Dermatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Rheumatology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Oncology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)

NO20060189A 2003-06-23 2006-01-12 Antistoffer mot interleukin-22 og anvendelse derav NO20060189L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US48065203P	2003-06-23	2003-06-23
PCT/US2004/020833 WO2005000897A2 (en)	2003-06-23	2004-06-22	Antibodies against interleukin-22 and uses therefor

Publications (1)

Publication Number	Publication Date
NO20060189L true NO20060189L (no)	2006-03-20

Family

ID=33551931

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20060189A NO20060189L (no)	2003-06-23	2006-01-12	Antistoffer mot interleukin-22 og anvendelse derav

Country Status (19)

Country	Link
EP (1)	EP1644415B1 (pt)
JP (2)	JP2007537132A (pt)
KR (1)	KR20060022289A (pt)
CN (1)	CN1839157A (pt)
AT (1)	ATE490275T1 (pt)
AU (1)	AU2004252169A1 (pt)
BR (1)	BRPI0411784A (pt)
CA (1)	CA2530386A1 (pt)
CR (1)	CR8211A (pt)
DE (1)	DE602004030341D1 (pt)
EC (1)	ECSP066297A (pt)
ES (1)	ES2354693T3 (pt)
IL (1)	IL172646A0 (pt)
MX (1)	MXPA05013881A (pt)
NI (1)	NI200500230A (pt)
NO (1)	NO20060189L (pt)
RU (1)	RU2006101702A (pt)
WO (1)	WO2005000897A2 (pt)
ZA (1)	ZA200600608B (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU740405B2 (en)	1998-05-15	2001-11-01	Genentech Inc.	IL-17 homologous polypeptides and therapeutic uses thereof
US7771719B1 (en)	2000-01-11	2010-08-10	Genentech, Inc.	Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7718397B2 (en)	2000-03-21	2010-05-18	Genentech, Inc.	Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
US20030096969A1 (en)	2000-06-02	2003-05-22	Genentech, Inc.	Secreted and transmembrane polypeptides and nucleic acids encoding the same
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
EP2784084B2 (en)	2003-07-08	2023-10-04	Novartis Pharma AG	Antagonist antibodies to IL-17A/F heterologous polypeptides
HUE026260T2 (en)	2003-11-21	2016-06-28	Ucb Biopharma Sprl	A method for treating multiple sclerosis by inhibiting IL-17 activity
PL2407486T3 (pl)	2005-08-19	2018-05-30	Wyeth Llc	Przeciwciała antagonistyczne względem GDF-8 i zastosowania w leczeniu ALS i innych zaburzeń związanych z GDF-8
HRP20140240T4 (hr)	2005-11-30	2017-02-24	Abbvie Inc.	Monoklonalna antitijela protiv amiloidnih beta proteina i njihova upotreba
US8691224B2 (en)	2005-11-30	2014-04-08	Abbvie Inc.	Anti-Aβ globulomer 5F7 antibodies
BRPI0619118A2 (pt) *	2005-12-02	2011-09-13	Genentech Inc	composições e métodos para o tratamento de doenças e desordens associadas com a sinalização de citocina
AU2013200914B2 (en) *	2005-12-02	2016-01-14	Genentech, Inc.	Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
CN101573139A (zh) *	2006-02-16	2009-11-04	纳森特生物制剂公司	在哺乳动物个体中改善免疫功能的方法以及预防或治疗疾病的方法
TW200744634A (en) *	2006-02-21	2007-12-16	Wyeth Corp	Methods of using antibodies against human IL-22
TWI417301B (zh)	2006-02-21	2013-12-01	Wyeth Corp	對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
WO2007149814A1 (en) *	2006-06-19	2007-12-27	Wyeth	Methods of modulating il-22 and il-17
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en)	2007-02-27	2014-11-25	AbbVie Deutschland GmbH & Co. KG	Method for the treatment of amyloidoses
WO2008150885A1 (en) *	2007-05-29	2008-12-11	Board Of Regents, The University Of Texas System	Modulation of the th-17 cell mediated immune responses
CN101225110B (zh) *	2007-10-23	2010-10-20	中国人民解放军军事医学科学院基础医学研究所	人白细胞介素-22突变体及其构建方法和应用
KR101867606B1 (ko) *	2007-11-07	2018-06-18	제넨테크, 인크.	미생물 질환의 치료를 위한 조성물 및 방법
CA2718634A1 (en) *	2008-03-21	2009-09-24	Wyeth Llc	Antibodies against interleukin-10-like cytokines and uses therefor
RU2474588C2 (ru)	2008-05-05	2013-02-10	Новиммун Са	Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
CN102458437B (zh)	2009-05-05	2015-06-10	诺维莫尼公司	抗il-17f抗体及其使用方法
US8987419B2 (en)	2010-04-15	2015-03-24	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
EP3533803B1 (en)	2010-08-14	2021-10-27	AbbVie Inc.	Anti-amyloid-beta antibodies
AU2012253422B2 (en)	2011-05-10	2015-08-13	Société des Produits Nestlé S.A.	Methods of disease activity profiling for personalized therapy management
WO2014145016A2 (en)	2013-03-15	2014-09-18	Genentech, Inc.	Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EP4053557A1 (en) *	2016-11-24	2022-09-07	Huvet Bio, Inc.	Il-29 as a marker for a pancreatic disease
US20180251522A1 (en) *	2017-02-21	2018-09-06	The Regents Of The University Of Michigan	Il-22bp compositions and method for the treatment of disease therewith
EP3612843A1 (en)	2017-05-31	2020-02-26	Prometheus Biosciences, Inc.	Methods for assessing mucosal healing in crohn's disease patients
KR102536314B1 (ko) *	2018-05-23	2023-05-25	주식회사 휴벳바이오	질환의 진단용 조성물
KR20210019464A (ko)	2018-06-05	2021-02-22	바이오아트라, 인코퍼레이티드	항 il-22 항체, 항체 단편, 이의 면역접합체 및 이의 용도
EP4083058A3 (en) *	2018-11-07	2023-01-11	Applied Molecular Transport Inc.	Delivery constructs for transcytosis and related methods
AR124250A1 (es) *	2020-12-07	2023-03-01	UCB Biopharma SRL	Anticuerpos

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2002016611A2 (en) *	2000-08-24	2002-02-28	Genentech, Inc.	Interleukin-22 polypeptides, nucleic acids encoding the same and methods for the treatment of pancreatic disorders
US6939545B2 (en) *	1999-04-28	2005-09-06	Genetics Institute, Llc	Composition and method for treating inflammatory disorders
US20030170823A1 (en) *	1999-12-23	2003-09-11	Presnell Scott R.	Novel cytokine ZCYTO18
ES2349312T3 (es) *	2000-07-27	2010-12-29	Wyeth Llc	Uso de anticuerpos antagonistas del receptor de il-10 para inhibir la inducción por il-tif/il-21 de proteínas de fase aguda.
CA2438238A1 (en) *	2001-02-23	2002-09-06	Genetics Institute, Llc.	Composition comprising il-22 inhibitors and use thereof for treating inflammatory disorders

2004
- 2004-06-22 EP EP04756337A patent/EP1644415B1/en not_active Expired - Lifetime
- 2004-06-22 AT AT04756337T patent/ATE490275T1/de not_active IP Right Cessation
- 2004-06-22 CN CNA2004800237577A patent/CN1839157A/zh not_active Withdrawn
- 2004-06-22 WO PCT/US2004/020833 patent/WO2005000897A2/en not_active Ceased
- 2004-06-22 RU RU2006101702/13A patent/RU2006101702A/ru not_active Application Discontinuation
- 2004-06-22 MX MXPA05013881A patent/MXPA05013881A/es active IP Right Grant
- 2004-06-22 DE DE602004030341T patent/DE602004030341D1/de not_active Expired - Lifetime
- 2004-06-22 ES ES04756337T patent/ES2354693T3/es not_active Expired - Lifetime
- 2004-06-22 JP JP2006517763A patent/JP2007537132A/ja active Pending
- 2004-06-22 CA CA002530386A patent/CA2530386A1/en not_active Abandoned
- 2004-06-22 KR KR1020057024826A patent/KR20060022289A/ko not_active Withdrawn
- 2004-06-22 BR BRPI0411784-0A patent/BRPI0411784A/pt not_active IP Right Cessation
- 2004-06-22 AU AU2004252169A patent/AU2004252169A1/en not_active Withdrawn
2005
- 2005-12-16 NI NI200500230A patent/NI200500230A/es unknown
- 2005-12-18 IL IL172646A patent/IL172646A0/en unknown
2006
- 2006-01-12 NO NO20060189A patent/NO20060189L/no not_active Application Discontinuation
- 2006-01-20 EC EC2006006297A patent/ECSP066297A/es unknown
- 2006-01-20 ZA ZA200600608A patent/ZA200600608B/en unknown
- 2006-01-23 CR CR8211A patent/CR8211A/es not_active Application Discontinuation
2007
- 2007-10-19 JP JP2007273219A patent/JP2008044966A/ja active Pending

Also Published As

Publication number	Publication date
AU2004252169A1 (en)	2005-01-06
MXPA05013881A (es)	2008-02-13
WO2005000897A3 (en)	2005-03-31
JP2007537132A (ja)	2007-12-20
JP2008044966A (ja)	2008-02-28
WO2005000897A2 (en)	2005-01-06
ECSP066297A (es)	2006-07-28
CR8211A (es)	2006-04-27
EP1644415B1 (en)	2010-12-01
EP1644415A2 (en)	2006-04-12
CA2530386A1 (en)	2005-01-06
ES2354693T3 (es)	2011-03-17
ATE490275T1 (de)	2010-12-15
NI200500230A (es)	2008-01-30
ZA200600608B (en)	2007-05-30
DE602004030341D1 (de)	2011-01-13
RU2006101702A (ru)	2006-09-10
IL172646A0 (en)	2006-04-10
KR20060022289A (ko)	2006-03-09
BRPI0411784A (pt)	2006-08-08
CN1839157A (zh)	2006-09-27

Legal Events

Date	Code	Title	Description
2011-01-31	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20060189L (no)	2006-03-20	Antistoffer mot interleukin-22 og anvendelse derav
ATE394121T1 (de)	2008-05-15	Verwendung von antikörpern gegen das muc18- antigen
EA201301072A1 (ru)	2014-06-30	Антитела против il-23p19 и их применение
DK1660458T3 (da)	2012-05-07	2, 4-pyrimidindiaminer egnede i behandling af neoplastiske sygdomme, in-flammatoriske lidelser og lidelser i immunsystemet.
EP1603949B8 (en)	2010-03-10	Antibodies against human il-21 receptor and uses therefor
WO2018226580A3 (en)	2019-01-31	ANTIBODIES SPECIFICALLY BINDING TO PD-1 AND THEIR METHODS OF USE
NZ605429A (en)	2014-08-29	Therapeutic human anti-il-1r1 monoclonal antibody
MY146664A (en)	2012-09-14	Antibodies against human il-22 and uses therefor
ATE488530T1 (de)	2010-12-15	Internalisierende antikörper spezifisch für das raag10 zelloberflächenziel
MX2008000030A (es)	2008-04-02	Metodos para el tratamiento de enfermedad autoinmune utilizando anticuerpos anti-cd16a humanizados.
PL1615952T3 (pl)	2012-03-30	Sposoby leczenia chorób zapalnych z zastosowaniem środków specyficznie wiążących ludzką angiopoetynę-2
CY1110689T1 (el)	2015-06-10	Συνθεσεις οι οποιες περιλαμβανουν πολυπεπτιδια
MXPA02000119A (es)	2003-07-21	Elementos mezcladores estaticos apilados.
DE60334453D1 (de)	2010-11-18	Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten
IS8451A (is)	2006-05-11	Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IN2014DN05011A (pt)	2015-07-10
EP2327423A3 (en)	2013-05-15	Human antibodies against human interleukin-22 (IL-22)
PL1848744T3 (pl)	2012-06-29	Ludzkie przeciwciała anty-interferon gamma i sposoby ich zastosowania
IL163902A0 (en)	2005-12-18	Antibodies against cancer antigen tmeff2 and uses thereof
DE60109430D1 (de)	2005-04-21	An entzündlichen darmerkrankungen beteiligte gene und deren verwendung
UA94211C2 (ru)	2011-04-26	Выделенное полностью человеческое моноклональное cd3 антитело
WO2024030956A3 (en)	2024-04-11	Cd39-specific binding agents and methods of using the same
IL177825A0 (en)	2006-12-31	Natural igm antibodies and inhibitors thereof
DK1483581T3 (da)	2008-03-17	Populationsbaserede vurderinger og midler til rangordning af proteiners relative immunogenicitet
WO2023166318A3 (en)	2023-10-12	Therapeutic antibodies